Human papillomavirus-associated antigens (HPV antigens)

Human papillomavirus (HPV)-associated antigens are viral proteins produced during the infection cycle of HPV, a double-stranded DNA virus that targets mucosal and cutaneous epithelia. These antigens are categorized into early (E) proteins, such as E1, E2, E6, and E7, and late (L) proteins, L1 and L2. The L1 protein is the primary component of the viral capsid and serves as the target for prophylactic vaccines, which induce neutralizing antibodies to prevent initial infection (National Cancer Institute, 2023). In contrast, the E6 and E7 proteins are high-risk oncoproteins that drive malignant transformation by degrading host tumor suppressors p53 and pRb, respectively (PubMed, PMID: 29115295). Because E6 and E7 are constitutively expressed in HPV-positive cancer cells but not in healthy tissues, they are ideal targets for therapeutic vaccines and T-cell-based immunotherapies. These treatments aim to break immune tolerance and induce a robust T-cell response against established tumors (Journal of Clinical Oncology, 2021). HPV-associated antigens are central to the management of several malignancies, most notably cervical and oropharyngeal cancers, where they serve as both diagnostic biomarkers and therapeutic focal points.

Other names

HPV proteinsHPV E6/E7 oncoproteinsHPV L1/L2 capsid proteinsHuman papillomavirus antigensHPV-derived antigens

Prophylactic vaccines utilize recombinant L1 capsid proteins to induce neutralizing antibodies that prevent viral entry into host cells (CDC, 2021). Therapeutic vaccines and immunotherapies target the E6 and E7 oncoproteins to stimulate a cellular immune response, specifically activating CD8+ cytotoxic T lymphocytes and CD4+ helper T cells to recognize and eliminate HPV-infected or malignant cells (PubMed, PMID: 30333116).